Pfizer PFE reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of 48 cents per share. The company had recorded earnings of 10 cents per share in...
Pfizer’s PFE non-COVID operational revenues improved in the first three quarters of 2024, driven by its key in-line products like Vyndaqel and Eliquis, new launches like Abrysvo and newly acquired products...
The stock is one of the renowned investor’s top holdings.
Pfizer PFE will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $17.50 billion...
How expensive is the stock market right now? The S&P 500 Shiller CAPE ratio is near its second-highest level ever. Its highest mark came in early 2000 before the dot-com bubble burst. The next-highest...
Nearly one year ago, I made four predictions about the stock market in 2024 . I thought the S&P 500 would generate positive returns but lower than in 2023. I didn't believe the so-called "Magnificent Seven"...
Retail sentiment on the stock leaned cautious as many commenters noted concerns regarding the mRNA prospects and BioNTech’s capabilities.
BioNTech (BNTX) has reached settlement agreements with the U.S. National Institutes of Health (NIH) and the University of Pennsylvania over royalties tied to its COVID-19 vaccine, resolving disputes over...
Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the inherent risks of developing new drugs.
Cathie Wood is shifting away from Tesla, zeroing in on an AI-driven healthcare firm that is revolutionizing precision medicine and advanced diagnostics.